Hdo And SO2 Thermal Mapping On Venus: Evidence For Strong SO2 Variability

We have been using the TEXES high-resolution imaging spectrometer at the NASA Infrared Telescope Facility to map sulfur dioxide and deuterated water over the disk of Venus. Observations took place on January 10-12, 2012. The diameter of Venus was 13 arcsec, with an illumination factor of 80%. Data were recorded in the 1344-1370 cm(-1) range (around 7.35 mu m) with a spectral resolving power of 80 000 and a spatial resolution of about 1.5 arcsec. In this spectral range, the emission of Venus comes from above the cloud top (z = 60-80 km). Four HDO lines and tens of SO2 lines have been identified in our spectra. Mixing ratios have been estimated from HDO/CO2 and SO2/CO2 line depth ratios, using weak neighboring transitions of comparable depths. The HDO maps, recorded on Jan. 10 and Jan. 12, are globally uniform with no significant variation between the two dates. A slight enhancement of the HDO mixing ratio toward the limb might be interpreted as a possible increase of the D/H ratio with height above the cloud level. The mean H2O mixing ratio is found to be 1.5 +/-0.75 ppm, assuming a D/H ratio of 0.0312 (i.e. 200 times the terrestrial value) over the cloud deck. The SO2 maps, recorded each night from Jan. 10 to Jan. 12, show strong variations over the disk of Venus, by a factor as high as 5 to 10. In addition, the position of the maximum SO2 mixing ratio strongly varies on a timescale of 24 h. The maximum SO2 mixing ratio ranges between 75 +/-25 ppb and 125 +/-50 ppb between Jan. 10 and Jan. 12. The high variability of sulfur dioxide is probably a consequence of its very short photochemical lifetime.NASA NNX-08AE38A, NNX08AW33G S03NSF AST-0607312, AST-0708074Astronom

HDO And SO2 Thermal Mapping On Venus II. The So2 Spatial Distribution Above And Within The Clouds

Sulfur dioxide and water vapor, two key species of Venus photochemistry, are known to exhibit significant spatial and temporal variations above the cloud top. In particular, ground-based thermal imaging spectroscopy at high spectral resolution, achieved on Venus in January 2012, has shown evidence for strong SO2 variations on timescales shorter than a day. We have continued our observing campaign using the TEXES high-resolution imaging spectrometer at the NASA InfraRed Telescope Facility to map sulfur dioxide over the disk of Venus at two different wavelengths, 7 mu m (already used in the previous study) and 19 mu m. The 7 mu m radiation probes the top of the H2SO4 cloud, while the 19 mu m radiation probes a few kilometers below within the cloud. Observations took place on October 4 and 5, 2012. Both HDO and SO2 lines are identified in our 7-mu m spectra and SO2 is also easily identified at 19 mu m. The CO2 lines at 7 and 19 mu m are used to infer the thermal structure. An isothermal/inversion layer is present at high latitudes (above 60 N and S) in the polar collars, which was not detected in October 2012. The enhancement of the polar collar in October 2012 is probably due to the fact that the morning terminator is observed, while the January data probed the evening terminator. As observed in our previous run, the HDO map is relatively uniform over the disk of Venus, with a mean mixing ratio of about 1 ppm. In contrast, the SO2 maps at 19 mu m show intensity variations by a factor of about 2 over the disk within the cloud, less patchy than observed at the cloud top at 7 mu m. In addition, the SO2 maps seem to indicate significant temporal changes within an hour. There is evidence for a cutoff in the SO2 vertical distribution above the cloud top, also previously observed by SPICAV/SOIR aboard Venus Express and predicted by photochemical models.NASA NNX-08AE38AIRTF AST-0607312, AST-0708074Astronom

Sunlight refraction in the mesosphere of Venus during the transit on June 8th, 2004

Many observers in the past gave detailed descriptions of the telescopic aspect of Venus during its extremely rare transits across the Solar disk. In particular, at the ingress and egress, the portion of the planet's disk outside the Solar photosphere has been repeatedly perceived as outlined by a thin, bright arc ("aureole"). Those historical visual observations allowed inferring the existence of Venus' atmosphere, the bright arc being correctly ascribed to the refraction of light by the outer layers of a dense atmosphere. On June 8th, 2004, fast photometry based on electronic imaging devices allowed the first quantitative analysis of the phenomenon. Several observers used a variety of acquisition systems to image the event -- ranging from amateur-sized to professional telescopes and cameras -- thus collecting for the first time a large amount of quantitative information on this atmospheric phenomenon. In this paper, after reviewing some elements brought by the historical records, we give a detailed report of the ground based observations of the 2004 transit. Besides confirming the historical descriptions, we perform the first photometric analysis of the aureole using various acquisition systems. The spatially resolved data provide measurements of the aureole flux as a function of the planetocentric latitude along the limb. A new differential refraction model of solar disk through the upper atmosphere allows us to relate the variable photometry to the latitudinal dependency of scale-height with temperature in the South polar region, as well as the latitudinal variation of the cloud-top layer altitude. We compare our measurements to recent analysis of the Venus Express VIRTIS-M, VMC and SPICAV/SOIR thermal field and aerosol distribution. Our results can be used a starting point for new, more optimized experiments during the 2012 transit event.Comment: Icarus, in pres

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies

World-leading science with SPIRou - the nIR spectropolarimeter / high-precision velocimeter for CFHT

SPIRou is a near-infrared (nIR) spectropolarimeter / velocimeter proposed as a new-generation instrument for CFHT. SPIRou aims in particular at becoming world-leader on two forefront science topics, (i) the quest for habitable Earth-like planets around very- low-mass stars, and (ii) the study of low-mass star and planet formation in the presence of magnetic fields. In addition to these two main goals, SPIRou will be able to tackle many key programs, from weather patterns on brown dwarf to solar-system planet atmospheres, to dynamo processes in fully-convective bodies and planet habitability. The science programs that SPIRou proposes to tackle are forefront (identified as first priorities by most research agencies worldwide), ambitious (competitive and complementary with science programs carried out on much larger facilities, such as ALMA and JWST) and timely (ideally phased with complementary space missions like TESS and CHEOPS). SPIRou is designed to carry out its science mission with maximum efficiency and optimum precision. More specifically, SPIRou will be able to cover a very wide single-shot nIR spectral domain (0.98-2.35 \mu m) at a resolving power of 73.5K, providing unpolarized and polarized spectra of low-mass stars with a ~15% average throughput and a radial velocity (RV) precision of 1 m/s.Comment: 12 pages, 5 figures, conference proceedings of the French Society of Astronomy and Astrophysics meeting 201

Study of the plutino object (208996) 2003 AZ84 from stellar occultations: size, shape and topographic features

We present results derived from four stellar occultations by the plutino object (208996) 2003~AZ$_{84}$, detected at January 8, 2011 (single-chord event), February 3, 2012 (multi-chord), December 2, 2013 (single-chord) and November 15, 2014 (multi-chord). Our observations rule out an oblate spheroid solution for 2003~AZ$_{84}$'s shape. Instead, assuming hydrostatic equilibrium, we find that a Jacobi triaxial solution with semi axes $(470 \pm 20) \times (383 \pm 10) \times (245 \pm 8)$~km % axis ratios $b/a= 0.82 \pm 0.05$ and $c/a= 0.52 \pm 0.02$, can better account for all our occultation observations. Combining these dimensions with the rotation period of the body (6.75~h) and the amplitude of its rotation light curve, we derive a density $\rho=0.87 \pm 0.01$~g~cm$^{-3}$ a geometric albedo $p_V= 0.097 \pm 0.009$. A grazing chord observed during the 2014 occultation reveals a topographic feature along 2003~AZ$_{84}$'s limb, that can be interpreted as an abrupt chasm of width $\sim 23$~km and depth $> 8$~km or a smooth depression of width $\sim 80$~km and depth $\sim 13$~km (or an intermediate feature between those two extremes)

Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study

BACKGROUND: The leading cause of mortality for patients with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is the development of malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma. In the setting of NF1, this cancer type frequently arises from within its common and benign precursor, plexiform neurofibroma (PN). Transformation from PN to MPNST is challenging to diagnose due to difficulties in distinguishing cross-sectional imaging results and intralesional heterogeneity resulting in biopsy sampling errors. METHODS AND FINDINGS: This multi-institutional study from the National Cancer Institute and Washington University in St. Louis used fragment size analysis and ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA (cfDNA) to distinguish between MPNST and PN in patients with NF1. Following in silico enrichment for short cfDNA fragments and copy number analysis to estimate the fraction of plasma cfDNA originating from tumor (tumor fraction), we developed a noninvasive classifier that differentiates MPNST from PN with 86% pretreatment accuracy (91% specificity, 75% sensitivity) and 89% accuracy on serial analysis (91% specificity, 83% sensitivity). Healthy controls without NF1 (participants = 16, plasma samples = 16), PN (participants = 23, plasma samples = 23), and MPNST (participants = 14, plasma samples = 46) cohorts showed significant differences in tumor fraction in plasma (P = 0.001) as well as cfDNA fragment length (P \u3c 0.001) with MPNST samples harboring shorter fragments and being enriched for tumor-derived cfDNA relative to PN and healthy controls. No other covariates were significant on multivariate logistic regression. Mutational analysis demonstrated focal NF1 copy number loss in PN and MPNST patient plasma but not in healthy controls. Greater genomic instability including alterations associated with malignant transformation (focal copy number gains in chromosome arms 1q, 7p, 8q, 9q, and 17q; focal copy number losses in SUZ12, SMARCA2, CDKN2A/B, and chromosome arms 6p and 9p) was more prominently observed in MPNST plasma. Furthermore, the sum of longest tumor diameters (SLD) visualized by cross-sectional imaging correlated significantly with paired tumor fractions in plasma from MPNST patients (r = 0.39, P = 0.024). On serial analysis, tumor fraction levels in plasma dynamically correlated with treatment response to therapy and minimal residual disease (MRD) detection before relapse. Study limitations include a modest MPNST sample size despite accrual from 2 major referral centers for this rare malignancy, and lack of uniform treatment and imaging protocols representing a real-world cohort. CONCLUSIONS: Tumor fraction levels derived from cfDNA fragment size and copy number alteration analysis of plasma cfDNA using ULP-WGS significantly correlated with MPNST tumor burden, accurately distinguished MPNST from its benign PN precursor, and dynamically correlated with treatment response. In the future, our findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations

Constraints on Charon's Orbital Elements from the Double Stellar Occultation of 2008 June 22

The original publication is available at http://iopscience.iop.org/1538-3881/International audiencePluto and its main satellite, Charon, occulted the same star on 2008 June 22. This event was observed from Australia and La Réunion Island, providing the east and north Charon Plutocentric offset in the sky plane (J2000): X= + 12,070.5 ± 4 km (+ 546.2 ± 0.2 mas), Y= + 4,576.3 ± 24 km (+ 207.1 ± 1.1 mas) at 19:20:33.82 UT on Earth, corresponding to JD 2454640.129964 at Pluto. This yields Charon's true longitude L= 153.483 ± 0fdg071 in the satellite orbital plane (counted from the ascending node on J2000 mean equator) and orbital radius r= 19,564 ± 14 km at that time. We compare this position to that predicted by (1) the orbital solution of Tholen & Buie (the "TB97" solution), (2) the PLU017 Charon ephemeris, and (3) the solution of Tholen et al. (the "T08" solution). We conclude that (1) our result rules out solution TB97, (2) our position agrees with PLU017, with differences of ΔL= + 0.073 ± 0fdg071 in longitude, and Δr= + 0.6 ± 14 km in radius, and (3) while the difference with the T08 ephemeris amounts to only ΔL= 0.033 ± 0fdg071 in longitude, it exhibits a significant radial discrepancy of Δr= 61.3 ± 14 km. We discuss this difference in terms of a possible image scale relative error of 3.35 × 10-3in the 2002-2003 Hubble Space Telescope images upon which the T08 solution is mostly based. Rescaling the T08 Charon semi-major axis, a = 19, 570.45 km, to the TB97 value, a = 19636 km, all other orbital elements remaining the same ("T08/TB97" solution), we reconcile our position with the re-scaled solution by better than 12 km (or 0.55 mas) for Charon's position in its orbital plane, thus making T08/TB97 our preferred solution

Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines

Because of the low overall response rates of 10-47% to targeted cancer therapeutics, there is an increasing need for predictive biomarkers. We aimed to identify genes predicting response to five already approved tyrosine kinase inhibitors. We tested 45 cancer cell lines for sensitivity to sunitinib, erlotinib, lapatinib, sorafenib and gefitinib at the clinically administered doses. A resistance matrix was determined, and gene expression profiles of the subsets of resistant vs. sensitive cell lines were compared. Triplicate gene expression signatures were obtained from the caArray project. Significance analysis of microarrays and rank products were applied for feature selection. Ninety-five genes were also measured by RT-PCR. In case of four sunitinib resistance associated genes, the results were validated in clinical samples by immunohistochemistry. A list of 63 top genes associated with resistance against the five tyrosine kinase inhibitors was identified. Quantitative RT-PCR analysis confirmed 45 of 63 genes identified by microarray analysis. Only two genes (ANXA3 and RAB25) were related to sensitivity against more than three inhibitors. The immunohistochemical analysis of sunitinib-treated metastatic renal cell carcinomas confirmed the correlation between RAB17, LGALS8, and EPCAM and overall survival. In summary, we determined predictive biomarkers for five tyrosine kinase inhibitors, and validated sunitinib resistance biomarkers by immunohistochemistry in an independent patient cohort. © 2013 Pénzváltó et al